Yoseph RB, et al. - Among children born at 29–32 weeks of gestation (WGA), researchers assessed airway hyper-reactivity, systemic inflammatory markers, allergic parameters and respiratory morbidity, 5-7 years after treatment with palivizumab. At age 5-7 years, they examined children born at 29–32 WGA. They compared methacholine challenge test (MCT), serum inflammatory cytokines, fractional exhaled nitric oxide (FeNO), blood tests for eosinophil count, IgE and evaluation of respiratory morbidity between those born before palivizumab prophylaxis was extended to 29–32 WGA vs those who received palivizumab prophylaxis. Overall 27/42 children received palivizumab and remaining did not. Long-term respiratory morbidity, airway reactivity or allergic parameters were not beneficially influenced among children who received palivizumab vs children who did not receive immunoprophylaxis. Also, higher levels of Th2 and Th17 cytokines, implicated in asthma pathogenesis, were observed in those who received palivizumab. As per findings, the potential long-term beneficial impact of palivizumab on asthma onset is doubtful.